UNIVERSITE DE MONTPELLIER;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM);GAMAMABS PHARMA;INSTITUT REGIONAL DU CANCER DE MONTPELLIER
The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65 % of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.